Heidi Ahman
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Estimated Number of Symptomatic Lyme Borreliosis Cases in Adults in Finland in 2021 Using Seroprevalence Data to Adjust the Number of Surveillance-Reported Cases: A General Framework for Accounting for Underascertainment by Public Health Surveillance.
Journal: Vector borne and zoonotic diseases (Larchmont, N.Y.)
Published: April 18, 2023
Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.
Journal: Infectious diseases and therapy
Published: November 27, 2019
Exploring the costs of a 13-valent pneumococcal conjugate vaccination program for home care patients.
Journal: Current medical research and opinion
Published: August 18, 2018
Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions.
Journal: Journal of evaluation in clinical practice
Published: March 27, 2014
Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy.
Journal: Clinical and vaccine immunology : CVI
Published: May 10, 2013
Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age.
Journal: The Pediatric infectious disease journal
Published: February 11, 2005
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.
Journal: Infection and immunity
Published: December 25, 2004
Showing 1-8 of 8
Last Updated: 09/26/2026